Compass Ion Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Compass Ion Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$216K	Sell	3,752 -37	-1%	-$2.13K	0.02%	279
2026 Q1	$230K	Buy	3,789 +25	+0.7%	+$1.46K	0.02%	256
2025 Q4	$203K	Buy	+3,764	New	+$181K	0.02%	265
2025 Q2	–	Sell	-3,763	Closed	-$229K	–	269
2025 Q1	$229K	Buy	3,763 +50	+1%	+$2.91K	0.03%	236
2024 Q4	$210K	Buy	+3,713	New	+$207K	0.02%	246
2024 Q3	–	Sell	-4,485	Closed	-$243K	–	263
2024 Q2	$243K	Hold	4,485	–	–	0.03%	205
2024 Q1	$243K	Sell	4,485 -1	-0%	-$51	0.04%	205
2023 Q4	$230K	Sell	4,486 -273	-6%	-$14.3K	0.04%	210
2023 Q3	$276K	Buy	+4,759	New	+$292K	0.05%	192

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Compass Ion Advisors's BMY Position: Q2 2026 in Review

Compass Ion Advisors reduced its Bristol-Myers Squibb (BMY) stake by 0.98% in Q2 2026, selling an estimated $2.13K and leaving 3,752 shares worth $216K. The position accounts for 0.02% of the portfolio, ranked #279.

Compass Ion Advisors first reported a position in BMY in Q3 2023 and has held it in 9 quarters since. The position peaked at $276K in Q3 2023. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Compass Ion Advisors held 3,752 shares of Bristol-Myers Squibb worth $216K as of Q2 2026.
Compass Ion Advisors sold 37 Bristol-Myers Squibb shares in Q2 2026, an estimated $2.13K.
Bristol-Myers Squibb made up 0.02% of Compass Ion Advisors's portfolio in Q2 2026, its #279 holding.
Compass Ion Advisors first reported a position in Bristol-Myers Squibb in Q3 2023 and has held it in 9 quarters since.
Compass Ion Advisors's Bristol-Myers Squibb position peaked at $276K in Q3 2023.
2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Compass Ion Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.